Discovery of ligands for disrupting the SARS-CoV-2 interactome with human proteins using multipronged genetically encoded technologies

The proposed project will accelerate the drug development capabilities of 48Hour Discovery INC (48HD) to find high affinity drug candidates for treatment of COVID. The deliverable for this project will be high potential new drug candidates from 48HD’s drug discovery pipeline for COVID and other targets using unique molecular libraries of 48HD. The libraries are stable and resilient to stimulated gastrointestinal conditions and thus, the discovery platform will provide potentially oral and bioavailable therapeutics. In addition, 48HD has COVID collaborations with two research groups at the University of Alberta as well as with a number of companies in Canada and the United States in the who also have COVID related drug discovery programs underwa

Arunika Ekanayake
Faculty Supervisor: 
Ratmir Derda;Matthew Macauley
Partner University: